Tri-Cities Tech Business Update
*Advanced Medical Isotope Corporation and Battelle tackling cancer treatment
Advanced Medical Isotope Corporation (Pink Sheets:ADMD) is teaming with others to further develop its proprietary prostate cancer treatment. Battelle, which operates the Pacific Northwest National Laboratory in Richland, Wash., and the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah are both working with AMIC to develop a proprietary technology for controlled delivery of yttrium-90 microspheres embedded in resorbable seed-shape materials for tissue-directed, high-dose intra-tumor therapy. The controlled delivery method is expected to help minimize the radiation dose to nearby normal tissues and may significantly lower costs compared to existing alternatives. In related news, James C. Katzaroff, current president of Advanced Medical Isotope Corporation, recently became the company's chief executive officer, with former CEO William Stokes assuming the role of president. The change reflects the company's plan for company growth. Contact Jim Katzaroff at (509) 736-4000.
